Quarterly Sales and EPS Roundup:
Boston Scientific Corporation (NYSE:BSX) reported sales (ttm) of 8.17 Billion, whereas, 22 number of analysts estimated the mean sale of 2164.93 million. The analysts estimated sales for the higher end at 2187 million and lower end at 2141.13 million while the year ago reported sale was 2097.38 million.
10 number of analysts have estimated the sales of the company for the quarter ending Feb 2, 2017- Feb 6, 2017, analysts estimated mean sale target of 2090.04 million while high and low sale targets are estimated at 2129 million and 2066 million respectively.
Boston Scientific Corporation (NYSE:BSX) reported earning per shares for the quarter ending Oct 26 BMO at 0.27, whereas, 25 number of analysts estimated the mean EPS at 0.29. The analysts estimated EPS for the higher end at 0.3 and lower end at 0.28 while the year ago reported earnings per share was 0.28.
The company has mean EPS estimate of 0.3 reported by 16 number of analyst for the quarter ending Feb 2, 2017- Feb 6, 2017. The analysts estimated mean EPS at 0.3 while the high and low EPS estimate stand at 0.31 and 0.28 respectively. In contrast to the year ago quarter EPS was at 0.28. EPS long term mean growth rate estimated by 7 analysts is at 12.78%, whereas, the high and low Long term growth rate estimated at 17.5 and 8.6.
Valuation Ratios of Boston Scientific Corporation (NYSE:BSX) versus the Industry and Sector:
Let’s have a look at some of the important valuation ratios of the Boston Scientific Corporation (NYSE:BSX). These ratios are important while doing valuation of the company or the shares of the company.
Boston Scientific Corporation (NYSE:BSX) currently has P/E (Price to Earnings) ratio of 376.43 while the company’s industry has 46.95 P/E and the sector P/E is 29.87. Similarly, the company’s last 5 years high P/E ratio is 18.39 and low P/E is 18.39, whereas, the industry’s and sector’s high P/E for the past year is 70.97 and 43.94 respectively and low P/E ratio for the last 5 years is 23.48 for the industry and 19.95 for the Sector.
Beta is also an important valuation ratio for analyzing the stock of the company, 21 has Beta of 1.12 while its industry and Sector’s beta remains at 0.82 and 0.83 respectively.
Price to Sale ratio of 21 stands at 3.58 while Price to Book Ratio stands at 4.51. Its Price to Cash Flow ratio shows the value of 38.35, whereas, the industry and sector ratio of Price to Cash Flow ticked at 17.59 and 22.64 respectively.
5 Year Growth Rate Analysis:
Growth rates are very important while analyzing the long term growth and valuation of a certain company.
5 year sales growth rate is an important factor for valuation analysis, the 5 year sales growth of Boston Scientific Corporation (NYSE:BSX) stands at -0.86 while the industry’s and the sector’s growth for next 5 years ticked at 4.29 and 10.88 respectively. The company’s 5 year Earnings per share growth and Capital Spending growth remains at 0 and 13.04.
Boston Scientific Corporation (NYSE:BSX) Trading Statistics:
The company declined -1.49% and closed its last trading session at $20.77. The market capitalization of the company is at $27.86 Billion. The stock touched 52-week High of $24.79 on Jul 28, 2016 and 52-week Low of $15.67 on Feb 8, 2016. The stock currently has Weekly Volatility of 1.63% and Monthly Volatility of 2.18%. The Beta for the company stands at 1.1 and its Average True Range (ATR) shows a value of 0.49.